These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9757793)

  • 21. [Fluoroquinolones, 10 years later].
    de la Blanchardière A; Carbon C
    Rev Prat; 1993 Sep; 43(14):1830-8. PubMed ID: 8310228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora.
    Richard P; Delangle MH; Raffi F; Espaze E; Richet H
    Clin Infect Dis; 2001 Jan; 32(1):162-6. PubMed ID: 11112677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluoroquinolones in respiratory infections.
    Klein NC
    Semin Respir Infect; 1991 Sep; 6(3):131-5. PubMed ID: 1754733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA withdraws approval of two poultry drugs.
    FDA Consum; 2001; 35(4):5. PubMed ID: 11692891
    [No Abstract]   [Full Text] [Related]  

  • 25. Effectiveness of fluoroquinolones against gram-positive bacteria.
    Bush K; Goldschmidt R
    Curr Opin Investig Drugs; 2000 Sep; 1(1):22-30. PubMed ID: 11249591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDA hastening withdrawal of fluoroquinolone approvals for poultry.
    J Am Vet Med Assoc; 2000 Nov; 217(10):1447, 1452. PubMed ID: 11128524
    [No Abstract]   [Full Text] [Related]  

  • 27. The fluoroquinolones.
    Walker RC
    Mayo Clin Proc; 1999 Oct; 74(10):1030-7. PubMed ID: 10918871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moxifloxacin: new preparation. A me-too with more cardiac risks.
    Prescrire Int; 2002 Dec; 11(62):168-9. PubMed ID: 12469694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A nosocomial outbreak of fluoroquinolone-resistant salmonella infection.
    Olsen SJ; DeBess EE; McGivern TE; Marano N; Eby T; Mauvais S; Balan VK; Zirnstein G; Cieslak PR; Angulo FJ
    N Engl J Med; 2001 May; 344(21):1572-9. PubMed ID: 11372008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluoroquinolone antibiotics.
    Kosier JH; Billeter M; Newton M
    Urol Nurs; 1998 Sep; 18(3):239-42. PubMed ID: 9873366
    [No Abstract]   [Full Text] [Related]  

  • 31. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones.
    Hwang DG
    Surv Ophthalmol; 2004 Mar; 49 Suppl 2():S79-83. PubMed ID: 15028483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects.
    Gootz TD; Brighty KE
    Med Res Rev; 1996 Sep; 16(5):433-86. PubMed ID: 8865150
    [No Abstract]   [Full Text] [Related]  

  • 33. [Broad-spectrum fluoroquinolones. Passed safety tests up to now].
    MMW Fortschr Med; 2001 Feb; 143(6):59. PubMed ID: 11247374
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of clonality in the global spread of fluoroquinolone-resistant bacteria.
    Klugman KP
    Clin Infect Dis; 2003 Mar; 36(6):783-5. PubMed ID: 12627363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New plasmid-mediated resistances to antimicrobial agents.
    Courvalin P
    Arch Microbiol; 2008 Apr; 189(4):289-91. PubMed ID: 18094959
    [No Abstract]   [Full Text] [Related]  

  • 36. Overview of the fluoroquinolone antibiotics.
    Just PM
    Pharmacotherapy; 1993; 13(2 Pt 2):4S-17S. PubMed ID: 8386356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Which partner for the betalactam agent in empiric combined therapy? I Fluoroquinolone].
    Bedos JP
    Ann Fr Anesth Reanim; 2004 Jun; 23(6):636-8. PubMed ID: 15234734
    [No Abstract]   [Full Text] [Related]  

  • 38. Role of newer broad-spectrum beta-lactam and fluoroquinolone antibiotics in children.
    Bonafede ME; Blumer JL
    Adv Pediatr Infect Dis; 1996; 12():71-108. PubMed ID: 9033976
    [No Abstract]   [Full Text] [Related]  

  • 39. Antimicrobial agents for complicated skin and skin-structure infections: noninferiority margins, placebo-controlled trials, and the complexity of clinical trials.
    Stevens DL
    Clin Infect Dis; 2009 Aug; 49(3):392-4. PubMed ID: 19555284
    [No Abstract]   [Full Text] [Related]  

  • 40. Every hour counts: Integrating rapid molecular analysis with antimicrobial stewardship in real time for gram-negative bacteremia.
    Onigman P
    MLO Med Lab Obs; 2013 Feb; 45(2):8-10; quiz 12. PubMed ID: 24133856
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.